PDF(Pubmed)
Abstract：
OBJECTIVE: To evaluate the effectiveness and safety of rivaroxaban anticoagulation in COVID-19 patients.
METHODS: PubMed, Embase, Cochrane Library electronic databases, and ClinicalTrials.gov were searched to identify all relevant randomized controlled trial studies from December 2019 to July 2023.
RESULTS: A total of 6 randomized controlled trials, which included a total of 3323 patients, were considered for evaluation. Overall, short-term all-cause mortality and hospitalization rates were not significantly different between the rivaroxaban and control groups. Thrombotic events were significantly reduced in the rivaroxaban prophylaxis group compared to the placebo control group. However, the reduction in thrombotic events was not significantly different between rivaroxaban therapy and heparin or low-molecular-weight heparin (LMWH). Rivaroxaban prophylaxis and the therapeutic dose may be associated with a higher rate of overall bleeding rate, but major bleeding rates did not differ substantially.
CONCLUSIONS: Rivaroxaban may reduce thrombotic events in COVID-19 patients, but it does not appear to have an advantage over heparin or LMWH, and it may increase the risk of bleeding.INPLASY Reg. No.: INPLASY 202370097.
METHODS: PubMed, Embase, Cochrane Library electronic databases, and ClinicalTrials.gov were searched to identify all relevant randomized controlled trial studies from December 2019 to July 2023.
RESULTS: A total of 6 randomized controlled trials, which included a total of 3323 patients, were considered for evaluation. Overall, short-term all-cause mortality and hospitalization rates were not significantly different between the rivaroxaban and control groups. Thrombotic events were significantly reduced in the rivaroxaban prophylaxis group compared to the placebo control group. However, the reduction in thrombotic events was not significantly different between rivaroxaban therapy and heparin or low-molecular-weight heparin (LMWH). Rivaroxaban prophylaxis and the therapeutic dose may be associated with a higher rate of overall bleeding rate, but major bleeding rates did not differ substantially.
CONCLUSIONS: Rivaroxaban may reduce thrombotic events in COVID-19 patients, but it does not appear to have an advantage over heparin or LMWH, and it may increase the risk of bleeding.INPLASY Reg. No.: INPLASY 202370097.
摘要：
目的：评价利伐沙班抗凝治疗COVID-19患者的有效性和安全性。
方法：PubMed，Embase,Cochrane图书馆电子数据库，和ClinicalTrials.gov进行搜索，以确定2019年12月至2023年7月的所有相关随机对照试验研究。
结果：共6项随机对照试验，其中包括3323名患者，被考虑进行评估。总的来说,利伐沙班组和对照组的短期全因死亡率和住院率无显著差异.与安慰剂对照组相比，利伐沙班预防组的血栓事件显著减少。然而,利伐沙班治疗与肝素或低分子肝素(LMWH)治疗之间血栓事件的减少无显著差异.利伐沙班的预防和治疗剂量可能与较高的总体出血率有关。但大出血率没有显著差异.
结论：利伐沙班可以减少COVID-19患者的血栓事件，但它似乎没有肝素或低分子肝素的优势，它可能会增加出血的风险。INPLASYReg.不。：INPLASY202370097。
方法：PubMed，Embase,Cochrane图书馆电子数据库，和ClinicalTrials.gov进行搜索，以确定2019年12月至2023年7月的所有相关随机对照试验研究。
结果：共6项随机对照试验，其中包括3323名患者，被考虑进行评估。总的来说,利伐沙班组和对照组的短期全因死亡率和住院率无显著差异.与安慰剂对照组相比，利伐沙班预防组的血栓事件显著减少。然而,利伐沙班治疗与肝素或低分子肝素(LMWH)治疗之间血栓事件的减少无显著差异.利伐沙班的预防和治疗剂量可能与较高的总体出血率有关。但大出血率没有显著差异.
结论：利伐沙班可以减少COVID-19患者的血栓事件，但它似乎没有肝素或低分子肝素的优势，它可能会增加出血的风险。INPLASYReg.不。：INPLASY202370097。
